Skip to content 
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. more
| Time Frame | TOVX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -17.27% | -1.08% | -1.38% |
| 1-Month Return | -13.33% | -0.47% | -1.81% |
| 3-Month Return | -35% | 2.13% | 1.38% |
| 6-Month Return | -58.64% | 17.04% | 5.68% |
| 1-Year Return | -89.42% | 6.56% | 11.74% |
| 3-Year Return | -99.31% | 16.78% | 65.15% |
| 5-Year Return | -99.93% | 34.34% | 73.68% |
| 10-Year Return | -100% | 137.88% | 260.03% |
| Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Cost of Revenue | 201.00K | 87.00K | 268.00K | 135.00K | 137.00K | [{"date":"2020-12-31","value":75,"profit":true},{"date":"2021-12-31","value":32.46,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":50.37,"profit":true},{"date":"2024-12-31","value":51.12,"profit":true}] |
| Gross Profit | (201.00K) | (87.00K) | (268.00K) | (135.00K) | (137.00K) | [{"date":"2020-12-31","value":-20100000,"profit":false},{"date":"2021-12-31","value":-8700000,"profit":false},{"date":"2022-12-31","value":-26800000,"profit":false},{"date":"2023-12-31","value":-13500000,"profit":false},{"date":"2024-12-31","value":-13700000,"profit":false}] |
| Gross Margin | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Operating Expenses | 10.16M | 14.27M | 21.58M | 21.43M | 26.35M | [{"date":"2020-12-31","value":38.56,"profit":true},{"date":"2021-12-31","value":54.18,"profit":true},{"date":"2022-12-31","value":81.91,"profit":true},{"date":"2023-12-31","value":81.34,"profit":true},{"date":"2024-12-31","value":100,"profit":true}] |
| Operating Income | (10.16M) | (14.27M) | (21.58M) | (21.43M) | (26.35M) | [{"date":"2020-12-31","value":-1016000000,"profit":false},{"date":"2021-12-31","value":-1427400000,"profit":false},{"date":"2022-12-31","value":-2158100000,"profit":false},{"date":"2023-12-31","value":-2143100000,"profit":false},{"date":"2024-12-31","value":-2634600000,"profit":false}] |
| Total Non-Operating Income/Expense | 88.00K | 12.00K | 983.00K | 2.88M | 1.39M | [{"date":"2020-12-31","value":3.05,"profit":true},{"date":"2021-12-31","value":0.42,"profit":true},{"date":"2022-12-31","value":34.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":48.2,"profit":true}] |
| Pre-Tax Income | (10.12M) | (14.27M) | (21.11M) | (19.99M) | (25.65M) | [{"date":"2020-12-31","value":-1011600000,"profit":false},{"date":"2021-12-31","value":-1426800000,"profit":false},{"date":"2022-12-31","value":-2111000000,"profit":false},{"date":"2023-12-31","value":-1998900000,"profit":false},{"date":"2024-12-31","value":-2565300000,"profit":false}] |
| Income Taxes | (117.00K) | (94.00K) | (1.43M) | (1.64M) | - | [{"date":"2020-12-31","value":-11700000,"profit":false},{"date":"2021-12-31","value":-9400000,"profit":false},{"date":"2022-12-31","value":-142500000,"profit":false},{"date":"2023-12-31","value":-164000000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income After Taxes | (10.00M) | (14.17M) | (19.68M) | (18.35M) | - | [{"date":"2020-12-31","value":-999900000,"profit":false},{"date":"2021-12-31","value":-1417400000,"profit":false},{"date":"2022-12-31","value":-1968500000,"profit":false},{"date":"2023-12-31","value":-1834900000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | (10.12M) | (14.27M) | (19.68M) | (19.31M) | (25.65M) | [{"date":"2020-12-31","value":-1011600000,"profit":false},{"date":"2021-12-31","value":-1426800000,"profit":false},{"date":"2022-12-31","value":-1968500000,"profit":false},{"date":"2023-12-31","value":-1930900000,"profit":false},{"date":"2024-12-31","value":-2565300000,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}] |
| Net Income | (10.04M) | (14.17M) | (19.68M) | (18.35M) | (25.65M) | [{"date":"2020-12-31","value":-1004300000,"profit":false},{"date":"2021-12-31","value":-1417400000,"profit":false},{"date":"2022-12-31","value":-1968500000,"profit":false},{"date":"2023-12-31","value":-1834900000,"profit":false},{"date":"2024-12-31","value":-2565300000,"profit":false}] |
| EPS (Diluted) | (6.10) | (2.10) | (1.27) | (1.17) | (29.35) | [{"date":"2020-12-31","value":-610,"profit":false},{"date":"2021-12-31","value":-210,"profit":false},{"date":"2022-12-31","value":-127,"profit":false},{"date":"2023-12-31","value":-117,"profit":false},{"date":"2024-12-31","value":-2935.07,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| TOVX | |
|---|---|
| Cash Ratio | 0.68 |
| Current Ratio | 0.90 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| TOVX | |
|---|---|
| ROA (LTM) | -29.21% |
| ROE (LTM) | -166.96% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| TOVX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.78 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.22 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| TOVX | |
|---|---|
| Trailing PE | 0.09 |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.96 |
| Price/FCF | NM |
| EV/R | 0.00 |
| EV/Ebitda | 1.72 |
Theriva Biologics Inc. (TOVX) share price today is $0.182
Yes, Indians can buy shares of Theriva Biologics Inc. (TOVX) on Vested. To buy
Yes, you can purchase fractional shares of Theriva Biologics Inc. (TOVX) via the Vested app. You can start investing in Theriva Biologics Inc. (TOVX) with a minimum investment of $1.
You can invest in shares of Theriva Biologics Inc. (TOVX) via Vested in three simple steps:
The 52-week high price of Theriva Biologics Inc. (TOVX) is $1.75. The 52-week low price of Theriva Biologics Inc. (TOVX) is $0.17.
The price-to-earnings (P/E) ratio of Theriva Biologics Inc. (TOVX) is 0.0876
The price-to-book (P/B) ratio of Theriva Biologics Inc. (TOVX) is 0.96
The dividend yield of Theriva Biologics Inc. (TOVX) is 0.00%
The market capitalization of Theriva Biologics Inc. (TOVX) is $6.44M
The stock symbol (or ticker) of Theriva Biologics Inc. is TOVX
Consider the share price of Theriva Biologics Inc. as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Theriva Biologics Inc. has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Theriva Biologics Inc. shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Theriva Biologics Inc. stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Theriva Biologics Inc. and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Theriva Biologics Inc. stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
